New drug made available early for men with advanced prostate cancer

NCT ID NCT03523338

NO_LONGER_AVAILABLE Disease control Sponsor: Aragon Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study provides early access to apalutamide for men whose prostate cancer has stopped responding to standard hormone therapy but has not yet spread. The goal is to gather more safety information while offering treatment before the drug is widely available. Participants must continue hormone therapy and have a rising PSA level.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

Centro Oncologico Estatal ISSEMYM

Toluca, 50180, Mexico
Ensino e Terapia de Inovacao Clinica AMO Etica

Salvador, 41950 640, Brazil
Farmaco Oncología especializada S.A. de C.V

Zapopan, 45050, Mexico
Fundacao Antonio Prudente A C Camargo Cancer Center

São Paulo, 01509 900, Brazil
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo

São Paulo, 01246 000, Brazil
Hospital Pablo Tobon Uribe

Medellín, 050034, Colombia
Instituto Nacional de Cancerologia

México, 14080, Mexico
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)

Rio de Janeiro, 22775 001, Brazil
Núcleo de Pesquisa São Camilo

São Paulo, 04014-002, Brazil
Oncologia Integral Satelite

Naucalpan, 53100, Mexico
Ynova Pesquisa Clinica

Florianópolis, 88020-210, Brazil
i Can Oncology Center

Monterrey, 64710, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.